Equity investment – Brl Speak http://brlspeak.net/ Wed, 28 Sep 2022 01:26:13 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://brlspeak.net/wp-content/uploads/2021/11/brl-160x160.png Equity investment – Brl Speak http://brlspeak.net/ 32 32 AnPac ​​Bio and New Investor Group Sign Equity Offering Totaling $3.67 Million https://brlspeak.net/anpac-bio-and-new-investor-group-sign-equity-offering-totaling-3-67-million/ Tue, 27 Sep 2022 02:52:01 +0000 https://brlspeak.net/anpac-bio-and-new-investor-group-sign-equity-offering-totaling-3-67-million/ PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — AnPac ​​Bio-Medical Science Co., Ltd. (“AnPac ​​Bio”, the “Company” or “we”) (ANPC), a biotechnology company operating in the United States and China focused on cancer screening and early detection, announced that on September 26, 2022, the Company and a group of nine institutional and individual investors (the “Investors”) […]]]>

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — AnPac ​​Bio-Medical Science Co., Ltd. (“AnPac ​​Bio”, the “Company” or “we”) (ANPC), a biotechnology company operating in the United States and China focused on cancer screening and early detection, announced that on September 26, 2022, the Company and a group of nine institutional and individual investors (the “Investors”) signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 million.

Pursuant to the various share purchase agreements, investors will invest in a private placement, in the aggregate, $3.67 million to purchase 36.7 million Class A shares of the Company. The investment is expected to be completed by the end of September 2022.

Dr. Chris Yu, co-chairman of the board and co-CEO of the company, said: “This equity investment is important to the company’s operations as well as research and development, including its trial clinic on class III medical devices. We believe these investments demonstrate continued confidence in the fundamental and long-term prospects of our company and its technology. We are entering the class III medical device critical clinical trial in three renowned hospitals. The success of this clinical trial and the receipt of a Class III medical device license are very important to our efforts to commercialize our cancer detection technology and assess the company. According to a 2021 report by US marketing and research firm Frost & Sullivan, we believe we have a very strong track record of innovation in addition to the world’s largest multiple cancer detection sample size (in the world). Next-Generation Cancer Detection Technologies Space).

About AnPac ​​Bio

AnPac ​​Bio is a biotechnology company focused on early cancer screening and detection, with 155 patents granted as of March 31, 2022. With two certified clinical laboratories in China and a CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomic tests. According to a report by Frost & Sullivan, AnPac ​​Bio ranked first in the world in terms of sample volume for screening tests and detection of multiple cancers (cumulative through January 2021). AnPac ​​Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For investor and media inquiries, please contact:

Company:

Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
E-mail: phil_case@AnPacbio.com

Investor Relations:

Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
E-mail: tina.xiao@ascent-ir.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform. of 1995 and relate to the future financial and operating performance of the Company. The Company has attempted to identify forward-looking statements by terminologies such as “believes”, “estimates”, “anticipates”, “expects”, “plans”, “projects”, “intends”, “potential”, “target”, “aim”, “predict”, “outlook”, “seek”, “goal”, “objective”, “assume”, “consider”, “continue”, “positioned”, “plan” , “probable”, “may”, “could”, “could”, “will”, “should”, “approximately” or other words that convey uncertainty of future events or results to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments regarding, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. These statements also involve known risks and unknowns, uncertainties and other factors that may cause the Company’s actual results to differ materially from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq listing rules, implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding market demand and acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technological developments; our ability to obtain and maintain regulatory approvals from the NMPA, FDA and relevant US states and to have our laboratories certified or accredited by authorities such as CLIA; our future business development, financial condition and results of operations and our ability to obtain financing on a cost-effective basis; potential changes in governmental regulations; general economic and business conditions in China and elsewhere; our ability to hire and retain key personnel; our relationships with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on economic and financial market conditions and our business and financial performance, as resulting from reduced business activities due to quarantines and travel restrictions instituted by China, the United States and many other countries around the world to contain the spread of the virus. In addition, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. United. Due to these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. Further, such statements speak only as of the date of this press release and, except as required by law, the Company undertakes no obligation to publicly revise or update any forward-looking statements for any reason. it would be.

main logo

]]>
AnPac ​​Bio and New Investor Group Sign Equity Offering Totaling $3.67 Million https://brlspeak.net/anpac-bio-and-new-investor-group-sign-equity-offering-totaling-3-67-million-2/ Tue, 27 Sep 2022 02:52:01 +0000 https://brlspeak.net/anpac-bio-and-new-investor-group-sign-equity-offering-totaling-3-67-million-2/ PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — AnPac ​​Bio-Medical Science Co., Ltd. (“AnPac ​​Bio”, the “Company” or “we”) (ANPC), a biotechnology company operating in the United States and China focused on cancer screening and early detection, announced that on September 26, 2022, the Company and a group of nine institutional and individual investors (the “Investors”) […]]]>

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — AnPac ​​Bio-Medical Science Co., Ltd. (“AnPac ​​Bio”, the “Company” or “we”) (ANPC), a biotechnology company operating in the United States and China focused on cancer screening and early detection, announced that on September 26, 2022, the Company and a group of nine institutional and individual investors (the “Investors”) signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 million.

Pursuant to the various share purchase agreements, investors will invest in a private placement, in the aggregate, $3.67 million to purchase 36.7 million Class A shares of the company. The investment is expected to be completed by the end of September 2022.

Dr. Chris Yu, co-chairman of the board and co-CEO of the company, said: “This equity investment is important to the company’s operations as well as research and development, including its trial clinic on class III medical devices. We believe these investments demonstrate continued confidence in the fundamental and long-term prospects of our company and its technology. We are entering the class III medical device critical clinical trial in three renowned hospitals. The success of this clinical trial and the receipt of a Class III medical device license are very important to our efforts to commercialize our cancer detection technology and assess the company. According to a 2021 report by US marketing and research firm Frost & Sullivan, we believe we have a very strong track record of innovation in addition to the world’s largest multiple cancer detection sample size (in the world). Next-Generation Cancer Detection Technologies Space).

About AnPac ​​Bio

AnPac ​​Bio is a biotechnology company focused on early cancer screening and detection, with 155 patents granted as of March 31, 2022. With two certified clinical laboratories in China and a CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomic tests. According to a report by Frost & Sullivan, AnPac ​​Bio ranked first in the world in terms of sample volume for screening tests and detection of multiple cancers (cumulative through January 2021). AnPac ​​Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For investor and media inquiries, please contact:

Company:

Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
E-mail: phil_case@AnPacbio.com

Investor Relations:

Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
E-mail: tina.xiao@ascent-ir.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform. of 1995 and relate to the future financial and operating performance of the Company. The Company has attempted to identify forward-looking statements by terminologies such as “believes”, “estimates”, “anticipates”, “expects”, “plans”, “projects”, “intends”, “potential”, “target”, “aim”, “predict”, “outlook”, “seek”, “goal”, “objective”, “assume”, “consider”, “continue”, “positioned”, “plan” , “probable”, “may”, “could”, “could”, “will”, “should”, “approximately” or other words that convey uncertainty of future events or results to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments regarding, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. These statements also involve known risks and unknowns, uncertainties and other factors that may cause the Company’s actual results to differ materially from those expressed or implied by any forward-looking statements. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq listing rules, implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding market demand and acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technological developments; our ability to obtain and maintain regulatory approvals from the NMPA, FDA and relevant US states and to have our laboratories certified or accredited by authorities such as CLIA; our future business development, financial condition and results of operations and our ability to obtain financing on a cost-effective basis; potential changes in governmental regulations; general economic and business conditions in China and elsewhere; our ability to hire and retain key personnel; our relationships with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on economic and financial market conditions and our business and financial performance, as resulting from reduced business activities due to quarantines and travel restrictions instituted by China, the United States and many other countries around the world to contain the spread of the virus. In addition, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. United. Due to these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. Further, such statements speak only as of the date of this press release and, except as required by law, the Company undertakes no obligation to publicly revise or update any forward-looking statements for any reason. it would be.

]]>
Vesa Equity Investment SA RL, a major shareholder of Foot Locker, Inc. (NYSE: FL), is selling 9,739 shares. – https://brlspeak.net/vesa-equity-investment-sa-rl-a-major-shareholder-of-foot-locker-inc-nyse-fl-is-selling-9739-shares/ Sat, 24 Sep 2022 15:53:46 +0000 https://brlspeak.net/vesa-equity-investment-sa-rl-a-major-shareholder-of-foot-locker-inc-nyse-fl-is-selling-9739-shares/ On September 20, Foot Locker, Inc. (NYSE: FL), which owns a significant stake in Foot Locker, Inc. (NYSE: FL), sold 9,739 shares. The average price paid for shares sold for a total of $380,113.17 was determined to be $39.03 per share. The total amount received for the shares was $380,113.17. Following the transaction, the insider […]]]>

On September 20, Foot Locker, Inc. (NYSE: FL), which owns a significant stake in Foot Locker, Inc. (NYSE: FL), sold 9,739 shares. The average price paid for shares sold for a total of $380,113.17 was determined to be $39.03 per share. The total amount received for the shares was $380,113.17. Following the transaction, the insider now owns 12,740,578 shares of the company, worth $497,264,759.34. You can find a copy of the filing that discloses the transaction on the Securities and Exchange Commission (SEC) website. The record described the transaction. People who hold more than 10% of a company’s shares are called “large shareholders”. They must file reports with the Securities and Exchange Commission.
Vesa Equity Investment SA of RL recently completed the following trade(s): On Friday, FL stock suffered a loss of $1.15, taking the price to $34.84. A total of 2,472,726 shares were traded by the company, which is significantly lower than the average volume of 2,913,566 shares, which were traded. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 7.11, a price-to-growth ratio of 0.27, and a beta value of 1.23. All of these metrics indicate that the stock is relatively expensive. Over the past year, Foot Locker, Inc.’s stock price has ranged from a high of $57.76 to a low of the same price. The company’s stock price moving average over the past 50 days is $33.23 and the stock price’s moving average over the past 200 days is $30.84. A 0.14 debt to equity ratio, a 0.42 general liquidity ratio to general liquidity ratio and a 1.46 general liquidity ratio to general liquidity ratio are all financial ratios.

The latest quarterly earnings report for Foot Locker, which trades on the NYSE under the ticker symbol FL, was released on Friday, August 19, 2018. The online athletic shoe retailer reported earnings per share for the quarter of $1.10, or $0.35. more than the consensus estimate of $0.75. The company’s quarterly revenue was $2.07 billion, which is in line with projections from industry experts, who expected the company to generate $2.07 billion in revenue. Foot Locker’s return on equity was 19.33% and the company’s net margin was 5.56%. The Company’s revenue for the quarter was down 9.2% from the same period last year. The company earned earnings per share of $2.21 in the same period a year earlier when the same period was compared. Those who follow the stock market expect Foot Locker, Inc. to generate earnings of $4.38 per share in 2017.

Additionally, the company announced that it will distribute its quarterly dividend on October 28. As a result, the company declared a dividend. On October 14, a dividend payment of $0.40 will be paid to shareholders whose information is on file with the company. This results in a return of 4.59% for the investment and an annual dividend payment of $1.60. Ex-dividend day is Thursday, October 13, very soon. Foot Locker’s (also known as DPR) dividend payout ratio currently stands at 32.65%.

Several research analysts working on the project have written and distributed recent reports on the company. On Sept. 1, Foot Locker’s rating that had been listed on StockNews.com as “hold” was changed to “sell,” indicating bearish sentiment towards the company. In a research note published Monday, August 22, William Blair reaffirmed a “hold” rating on Foot Locker shares and provided a price target of $29.00 for the company’s shares in a research note. . Additionally, the company provided a price target of $29.00. Following the recent rise in the company’s stock price, Robert W. Baird raised the price target he set for Foot Locker from $32.00 to $40.00 in a memo. research published August 22. On Monday, August 22, in a post research note, Cowen announced that they had raised their price target on Foot Locker from $29.00 to $35.00. In a research note published Tuesday, August 23, Foot Locker moved from a “neutral” rating to a “buy” rating and increased its price target from $29.00 to $39.00 in a research note. .
Additionally, they have increased the price target from $29.00 to $39.00. Twenty-one different ratings have been assigned to the stock by research analysts, including three buy ratings, nineteen hold ratings and two sell ratings. According to data provided by Bloomberg, the company’s average rating is “Hold” and the price target set for the stock is $41.70.

In recent times, institutional investors have seen both increases and decreases in the value of FL shares they hold in their portfolios. In the first three months of 2018, Renaissance Technologies LLC increased its stake in Foot Locker by 5,122.3%, through the purchase of additional shares. Shares of the athletic shoe retailer are now held by Renaissance Technologies LLC for a total of 913,900 shares, following the acquisition of an additional 896,400 shares in the last quarter. The current market value of these shares is $27,106,000. Additionally, Ceredex Value Advisors LLC added a new investment during the second quarter, with a size of approximately $11,179,000,000. This brought the company’s total investment in Foot Locker to approximately 11.1% of the company. Schonfeld Strategic Advisors LLC increased its stake in Foot Locker shares by 2,617.8% during the fourth quarter. After purchasing an additional 426,700 shares of the athletic shoe retailer’s stock last fiscal quarter, Schonfeld Strategic Advisors LLC now owns a total of 443,000 shares of the company’s stock, worth $19,320,000. The Northern Trust Corporation increased its stake in Foot Locker by 56.5% during the second quarter by purchasing additional shares. After buying an additional 398,312 shares of the athletic shoe retailer’s stock in the last fiscal quarter, Northern Trust Corp now owns 1,103,775 shares of the company’s stock. The current market value of these shares is $27,871,000. And finally, in the first three months of this year, Dimensional Fund Advisors LP increased the number of Foot Locker shares it held by 10.1%, making it the company’s largest holding. After purchasing an additional 389,754 shares in the last quarter, Dimensional Fund Advisors LP now owns 4,253,691 shares of the athletic shoe retailer, valued at $126,169,00. These shares were purchased for a total of $126,169.00. Institutional investors and hedge funds own 98.06% of the company’s shares, the vast majority.

]]>
Foot Locker, Inc. (NYSE: FL) Major shareholder Vesa Equity Investment SA RL sells 9,739 shares https://brlspeak.net/foot-locker-inc-nyse-fl-major-shareholder-vesa-equity-investment-sa-rl-sells-9739-shares/ Sat, 24 Sep 2022 00:47:54 +0000 https://brlspeak.net/foot-locker-inc-nyse-fl-major-shareholder-vesa-equity-investment-sa-rl-sells-9739-shares/ Foot Locker, Inc. (NYSE: FL – Get a rating) Major shareholder Vesa Equity Investment SA RL sold 9,739 Foot Locker shares in a trade on Tuesday, September 20. The shares were sold at an average price of $39.03, for a total value of $380,113.17. Following the completion of the transaction, the insider now owns 12,740,578 […]]]>

Foot Locker, Inc. (NYSE: FL – Get a rating) Major shareholder Vesa Equity Investment SA RL sold 9,739 Foot Locker shares in a trade on Tuesday, September 20. The shares were sold at an average price of $39.03, for a total value of $380,113.17. Following the completion of the transaction, the insider now owns 12,740,578 shares of the company, valued at $497,264,759.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, available at the SEC website. Large shareholders who own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Vesa Equity Investment SA RL has also recently carried out the following transaction(s):

  • On Thursday, September 22, Vesa Equity Investment SA RL sold 81,199 Foot Locker shares. The shares were sold at an average price of $36.74, for a total value of $2,983,251.26.

Foot Locker Stock Performance

FL stock traded at $1.15 during Friday’s trading, hitting $34.84. The company had a trading volume of 2,472,726 shares, compared to an average volume of 2,913,566. The company has a market capitalization of $3.25 billion, a PE ratio of 7.11, a price/earnings ratio of growth of 0.27 and a beta of 1.23. Foot Locker, Inc. has a 1 year minimum of $23.85 and a 1 year maximum of $57.76. The company has a 50-day moving average price of $33.23 and a 200-day moving average price of $30.84. The company has a quick ratio of 0.42, a current ratio of 1.46 and a debt ratio of 0.14.

Foot Locker (NYSE:FL- Get a rating) last released its quarterly results on Friday, August 19. The athletic shoe retailer reported earnings per share (EPS) of $1.10 for the quarter, beating the consensus estimate of $0.75 by $0.35. The company posted revenue of $2.07 billion for the quarter, versus $2.07 billion expected by analysts. Foot Locker had a return on equity of 19.33% and a net margin of 5.56%. The company’s revenue for the quarter was down 9.2% year over year. In the same quarter a year earlier, the company posted EPS of $2.21. On average, analysts expect Foot Locker, Inc. to post earnings per share of 4.38 for the current year.

Foot Locker announces dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 28. Investors of record on Friday, October 14 will receive a dividend of $0.40. This represents an annualized dividend of $1.60 and a yield of 4.59%. The ex-dividend date is Thursday, October 13. Foot Locker’s dividend payout ratio (DPR) is currently 32.65%.

Wall Street analysts predict growth

A number of research analysts have recently published reports on the company. StockNews.com downgraded Foot Locker from a “hold” rating to a “sell” rating in a Thursday, September 1, report. William Blair upgraded Foot Locker to a “hold” rating and set a price target of $29.00 on the stock in a Monday, August 22 research note. Robert W. Baird raised his price target on Foot Locker from $32.00 to $40.00 in a Monday, August 22 research note. Cowen raised his price target on Foot Locker from $29.00 to $35.00 in a Monday, August 22 research note. Finally, UBS Group raised its price target on Foot Locker from $29.00 to $39.00 and gave the company a “neutral” rating in a Tuesday, August 23 research note. Two research analysts rated the stock with a sell rating, nineteen gave the company a hold rating and three gave the company a buy rating. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $41.70.

Institutional investors weigh in on Foot Locker

A number of institutional investors have recently increased or reduced their stake in FL. Renaissance Technologies LLC increased its stake in Foot Locker by 5,122.3% in the 1st quarter. Renaissance Technologies LLC now owns 913,900 shares of the athletic shoe retailer valued at $27,106,000 after buying an additional 896,400 shares last quarter. Ceredex Value Advisors LLC purchased a new equity stake in Foot Locker during Q2 for a value of approximately $11,179,000. Schonfeld Strategic Advisors LLC increased its stake in Foot Locker by 2,617.8% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 443,000 shares of the athletic shoe retailer worth $19,328,000 after acquiring an additional 426,700 shares last quarter. Northern Trust Corp increased its stake in Foot Locker shares by 56.5% during the second quarter. Northern Trust Corp now owns 1,103,775 shares of the athletic shoe retailer worth $27,871,000 after acquiring an additional 398,312 shares last quarter. Finally, Dimensional Fund Advisors LP increased its holding in Foot Locker shares by 10.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,253,691 shares of the athletic shoe retailer worth $126,169,000 after acquiring 389,754 additional shares in the last quarter. Hedge funds and other institutional investors hold 98.06% of the company’s shares.

About Foot Locker

(Get a rating)

Foot Locker, Inc, through its subsidiaries, operates as an athletic footwear and apparel retailer. The company retails athletic footwear, apparel, accessories, equipment and team licensed products under the Foot Locker, Lady Foot Locker, Kids Foot Locker, Champs Sports, Eastbay, atmos, WSS, Footaction and Sidestep.

Further reading

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Foot Locker, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Foot Locker wasn’t on the list.

Although Foot Locker currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
American Equity Investment Life Holding (NYSE:AEL) Short interest down 8.4% in August https://brlspeak.net/american-equity-investment-life-holding-nyseael-short-interest-down-8-4-in-august/ Thu, 22 Sep 2022 00:00:00 +0000 https://brlspeak.net/american-equity-investment-life-holding-nyseael-short-interest-down-8-4-in-august/ American Equity Investment Life Holding (NYSE: AEL – Get a rating) was the target of a sharp decline in short-term interest in August. As of August 31, there was short interest totaling 2,290,000 shares, down 8.4% from the total of 2,500,000 shares as of August 15. Based on an average daily volume of 540,700 shares, […]]]>

American Equity Investment Life Holding (NYSE: AEL – Get a rating) was the target of a sharp decline in short-term interest in August. As of August 31, there was short interest totaling 2,290,000 shares, down 8.4% from the total of 2,500,000 shares as of August 15. Based on an average daily volume of 540,700 shares, the day-to-cover ratio is currently 4.2 days. About 2.7% of the stock’s shares are sold short.

A Wall Street analyst gives his opinion

A number of stock analysts have recently released reports on the stock. Raymond James raised its price target on shares of American Equity Investment Life from $40.00 to $48.00 and gave the stock an “outperform” rating in a Monday, August 15 research report. Piper Sandler cut her price target on American Equity Investment Life shares from $44.00 to $41.00 and set an “overweight” rating on the stock in a Friday, July 8 research note. Truist Financial raised its price target on American Equity Investment Life from $45.00 to $51.00 and gave the stock a “buy” rating in a Thursday, August 11 report. Evercore ISI downgraded American Equity Investment Life from an “outperform” rating to an “in line” rating and raised its share price target from $42.00 to $44.00 in a report on Monday 15 august. They noted that the move was a review call. Finally, Keefe, Bruyette & Woods downgraded American Equity Investment Life from an “outperform” rating to a “market performance” rating and reduced their target price for the stock from $43.00 to $41.00 in a report on Wednesday, July 13. Six equity research analysts gave the stock a hold rating and four gave the company a buy rating. Based on data from MarketBeat.com, American Equity Investment Life currently has a consensus rating of “Hold” and a consensus price target of $43.60.

American Equity Investment Life Stock down 0.8%

NYSE:AEL shares opened at $37.68 on Thursday. The company has a market capitalization of $3.30 billion, a price-earnings ratio of 3.19 and a beta of 1.04. The company has a debt ratio of 0.15, a current ratio of 0.16 and a quick ratio of 0.16. The company’s 50-day moving average is $37.82 and its 200-day moving average is $38.05. American Equity Investment Life has a 1 year minimum of $27.69 and a 1 year maximum of $44.49.

American Equity Investment Life (NYSE: AEL – Get a rating) last reported its quarterly earnings data on Monday, August 8. The financial services provider reported earnings per share (EPS) of $0.98 for the quarter, beating consensus analyst estimates of $0.71 by $0.27. The company posted revenue of $121.40 million for the quarter, versus a consensus estimate of $628.20 million. American Equity Investment Life achieved a return on equity of 8.22% and a net margin of 61.05%. The company’s revenues were down 88.7% from the same quarter last year. During the same period of the previous year, the company achieved EPS of $0.98. Equity research analysts expect American Equity Investment Life to post earnings per share of 3.78 for the current year.

Insider buying and selling

In related news, EVP Jeffrey D. Lorenzo sold 25,000 shares of the company in a transaction that took place on Tuesday, August 9. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the executive vice president now directly owns 36,439 shares of the company, valued at approximately $1,457,560. The transaction was disclosed in an SEC filing, which is available via the SEC website. 1.59% of the shares are held by insiders.

Institutional U.S. Equity Trading Investment Life

A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Castleview Partners LLC increased its stake in American Equity Investment Life by 282.0% in the second quarter. Castleview Partners LLC now owns 382 shares of the financial services provider worth $53,000 after buying an additional 282 shares in the last quarter. Congress Asset Management Co. MA increased its stake in American Equity Investment Life by 0.8% in the second quarter. Congress Asset Management Co. MA now owns 43,859 shares of the financial services provider valued at $1,604,000 after buying 330 additional shares in the last quarter. Byrne Asset Management LLC increased its stake in American Equity Investment Life to 95.9% in the first quarter. Byrne Asset Management LLC now owns 960 shares of the financial services provider valued at $38,000 after buying an additional 470 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in American Equity Investment Life by 3.8% in the first quarter. Mercer Global Advisors Inc. ADV now owns 13,745 shares of the financial services provider valued at $549,000 after buying 498 additional shares in the last quarter. Finally, Covestor Ltd increased its stake in American Equity Investment Life by 38.9% in the first quarter. Covestor Ltd now owns 2,180 shares of the financial services provider valued at $87,000 after buying an additional 610 shares in the last quarter. 93.16% of the shares are held by institutional investors.

American Equity Investment Life Insurance Company Profile

(Get a rating)

American Equity Investment Life Holding Company, through its subsidiaries, provides life insurance products in the United States. The company issues index and fixed rate annuities, as well as single premium immediate annuities. It markets its products through independent agents, including independent marketing organizations, broker/dealers, banks and registered investment advisers.

See also

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider American Equity Investment Life, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes over…and American Equity Investment Life was not on the list.

Although American Equity Investment Life currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Equity investment | Global economy: What will happen to your equity investments if the global economy is heading for a downturn? https://brlspeak.net/equity-investment-global-economy-what-will-happen-to-your-equity-investments-if-the-global-economy-is-heading-for-a-downturn/ Wed, 21 Sep 2022 08:00:00 +0000 https://brlspeak.net/equity-investment-global-economy-what-will-happen-to-your-equity-investments-if-the-global-economy-is-heading-for-a-downturn/ A recession is coming. The European Central Bank’s (ECB) unprecedented rate hike of 75 basis points, with further hikes on the horizon, is a sign that Europe should prepare for a long and painful winter ahead. With the US market in the doldrums and the European market facing runaway inflation, there seems to be little […]]]>
A recession is coming. The European Central Bank’s (ECB) unprecedented rate hike of 75 basis points, with further hikes on the horizon, is a sign that Europe should prepare for a long and painful winter ahead.

With the US market in the doldrums and the European market facing runaway inflation, there seems to be little to no respite for global markets experiencing one misfortune after another. Stimulus packages announced by several Western countries in response to Covid have now significantly increased their respective debts.

The effects of Covid-19, the crude oil spike, supply issues, chip shortages, the Russian-Ukrainian war, etc., have all caused disruption on a colossal level that seems to be derailing the global market. Heat waves across the world threaten to impact agricultural production as well as nuclear and hydroelectric operations. In addition, Russia recently pressured Europe by saying it would stop natural gas exports and ban Ukraine from exporting grain.

Despite several statements from global central banks attempting to appease the public, inflation has never been transitory. We are seeing continued increases in interest rates, leading us to believe that inflation is more persistent. China, the engine of global growth and global consumer of nearly 72% of iron ore production, 55% of refined copper and others, has slowed significantly, which has had a significant impact on the global economy.

Even to this day, many Chinese provinces are in lockdown. All of these factors have confused people wondering if the global economy is on the verge of collapse. Currency depreciation in many countries has also increased the import bill. You’re not alone if you’re wondering what will happen to your equity investments. That’s a good question to ask.

India’s inflation versus the world
A PMI level above 50 indicates an expanding economy, below 50 indicates that the economy is contracting. 50 is the determining line that decides the feelings of consumers. Take, for example, the composite PMI for the US at 44.6 and the UK at 44.6. Japan is at 49.4, while China is at 51.7, continuing to fall. There is a high probability that China’s composite PMI could fall further below 50.

The only silver lining is India’s composite PMI which sits at 58.2 and rising. Moreover, India is the only country among major economies where inflation is stable with a downward bias. India has a rare combination in the world where GDP growth would be high and inflation under control.

The RBI may announce its latest rate hike, but global economies may be subject to further rate hikes on an ongoing basis. Additionally, there is a 75% chance that the US Fed will announce another 75 basis point rate hike, which could further exacerbate the global economy. Additionally, some experts believe it would create more pressure on emerging market currencies.

So while neighboring countries such as Pakistan, Bangladesh and Sri Lanka are going through difficult times, the IMF’s projection that India’s GDP will reach 6.1% is the highest in the world among the greater savings.

We think China’s GDP could grow by less than 4%, and any forecast would otherwise be very optimistic.

No sadness or unhappiness, yet
Contrary to apocalypse advocates, we don’t believe the global economy is headed for collapse. On the contrary, we believe that the pain is likely to linger, especially for countries that do not take corrective action to rectify their policies or reforms.

Some European countries have offered subsidies to reduce the burden of fuel and electricity costs, but this only adds to their deficits. How to balance their income without raising taxes will be difficult. Things may get tough, but we believe the global economy is not headed for collapse.

As for India, we are unlikely to experience the pain that the world will experience. Moody’s Investor Service kept India’s sovereign credit rating with a stable outlook and said India’s recovery would not be derailed despite the Russian-Ukrainian military conflict, global inflation or even tighter security policies. countries like the United States.

But we believe the situation is very dynamic and we need to watch global developments with a keen eye. While the state of the global economy might affect India to some degree, it would have a limited impact.

This is where the Indian government has been very proactive. Whether it’s steel, wheat or sugar policies. The government moved quickly to ensure that the domestic consumption story did not suffer. Their preemptive actions testify to India’s inflation traction steadily declining for three consecutive months.

The government has additional plans to roll out reforms such as production-linked incentive schemes to ensure that Atma Nirman Bharat is a game-changer.

Indian stock market: an outlier
While the first half of 2022 has been tough for Indian equity investors, the second half has started to deliver returns. Dow and Nasdaq dip steadily, but the Indian market is in the green.

India would continue to be an oddity in terms of stock market performance. Global economies will struggle, but India will see gains. We have seen FIIs come back to India and have the opportunity to generate alpha. The shift will take place from West to East, where India will be a major player.

The equity market is a leading indicator, not a lag indicator, clearly showing that India will rise. So now is the time to get ready to take advantage of the rise in the Indian stock market, bet on India and stay invested in Indian stocks.

(Sunil Damania is Chief Investment Officer at MarketsMojo.)

]]>
In conversation with Sailesh Raj Bhan, Deputy CIO, Equity Investments, Nippon India Mutual Fund https://brlspeak.net/in-conversation-with-sailesh-raj-bhan-deputy-cio-equity-investments-nippon-india-mutual-fund/ Sat, 17 Sep 2022 09:49:03 +0000 https://brlspeak.net/in-conversation-with-sailesh-raj-bhan-deputy-cio-equity-investments-nippon-india-mutual-fund/ Considering the current domestic and global scenarios, Sailesh Raj Bhan, Deputy CIO (Equity Investments), Nippon India Mutual Fund has some advice for investors What is your outlook for the Indian equity markets in the […]]]>















Considering the current domestic and global scenarios, Sailesh Raj Bhan, Deputy CIO (Equity Investments), Nippon India Mutual Fund has some advice for investors





What is your outlook for the Indian equity markets in the short to medium term?


India’s economy appears well positioned for reasonable growth supported by normalizing demand and reviving industry. Policy reforms in recent years, huge underinvestment in capital spending, stronger corporate balance sheets, and a transition to a multipolar world can help manufacturing, exports, and capital spending , potentially creating a virtuous circle of growth. However, near-term market sentiment could potentially be affected by headwinds like the global slowdown, particularly in Europe, the US and China, as well as higher interest rates, higher energy costs , etc. After the recent sharp rise in equities, the market has re-evaluated and will keep pace with the recovery in earnings, as several re-evaluations have already taken place.



The Nippon India Multi-Cap Fund recently closed 17 years with a compound annual return of 16.42% since inception. Can you shed some light on the fund’s opportunistic investment style that has consistently outperformed broader markets?


The Nippon Multi-Cap Fund follows the investment philosophy of buying good quality companies that are growing at reasonable valuations. The framework is to avoid overpaying for growth unless justified by underlying cash flow growth. We avoid pure momentum bets where current valuations broadly reflect estimated medium-term growth. More importantly, the portfolio is constructed with a medium-term perspective and the objective is to take advantage of any significant market distortions without compromising the quality of the portfolio. Investing with high conviction, taking the right risk, not overpaying for growth and investing with a long-term view were among the main contributors to the fund’s long-term performance.



What changes have you made to your equity funds given the rise in interest rates and the volatility of recent months? Also, are you currently more geared towards growth or value stocks in the Nippon India Multi-Cap Fund?


The Nippon India Multi-Cap Fund follows the growth-at-a-reasonable-value philosophy with an emphasis on identifying quality companies with strong growth visibility. The attempt is to take the right risk without compromising quality and to invest early in the cycle to benefit significantly from the turnaround or recovery. In our view, it is extremely difficult to gauge very short-term or event-based market reactions and therefore we continue to build portfolios with a medium-term horizon in mind. Risk is managed through adequate diversification and a preference for quality companies at reasonable valuations with improved business prospects over high value companies given rising rates. The portfolio includes an optimal mix of established companies, potentially faster growing emerging leaders as well as a mix of cyclical and secular themes providing an appropriate balance.



In your view, what are the relevant risks facing equity markets in S2FY23?


Given the reliance on oil imports, the price of crude oil is a key risk to watch. Another challenge is the growing trade deficit of around $28 million, which has more than doubled in the past 12 months. A steeper-than-expected slowdown, especially a hard landing in the developed world, can affect global trade and investors’ risk appetite. However, in our experience, risks and opportunities generally go hand in hand and proper asset allocation and disciplined medium-term investing can go a long way to improving investors’ experience through market phases.



What are the top three emerging investment trends that you think will dominate over the next decade?


Long-term opportunities continue to emerge in many sectors given India’s low penetration per capita and the continuous reforms that are being implemented. Manufacturing and the recovery of capital spending, logistics, domestic pharmaceuticals, and the hospitality and travel sectors are important long-term growth themes.



How should retail investors manage today’s market volatility with mutual funds?


Volatility is the friend of a prepared investor. While the market may remain volatile in the short term given global shifts, the fundamental strength and demographic advantages of the domestic economy may play out in the medium to long term. As a result, retail investors can consider participating in equity-focused funds through laddered investments through SIPs or STPs. Since we believe broader markets can do well with current fundamentals, long-term investors can consider diversified strategies such as multi-cap or flexi-cap offerings for pure equity investments.



























]]>
Compass Minerals Announces Equity Investment Partnership with Koch Minerals & Trading https://brlspeak.net/compass-minerals-announces-equity-investment-partnership-with-koch-minerals-trading/ Fri, 16 Sep 2022 10:33:34 +0000 https://brlspeak.net/compass-minerals-announces-equity-investment-partnership-with-koch-minerals-trading/ Koch Minerals & Trading, LLC (KM&T) has agreed to make a US$252 million strategic equity investment in Compass Minerals through the purchase of common stock of Compass Minerals. KM&T, a diversified global trading, logistics and investment company, and subsidiary of Koch Industries, Inc. (KII), is making the investment to support phase one development of the […]]]>

Koch Minerals & Trading, LLC (KM&T) has agreed to make a US$252 million strategic equity investment in Compass Minerals through the purchase of common stock of Compass Minerals.

KM&T, a diversified global trading, logistics and investment company, and subsidiary of Koch Industries, Inc. (KII), is making the investment to support phase one development of the previously identified $2.4 million resource tons of lithium carbonate equivalent (LCE) from Compass Minerals on the Great Salt Lake.

“We are delighted to welcome KM&T as an investment partner and look forward to leveraging their deep expertise and proven track record of value creation,” said Kevin S. Crutchfield, President and Chief direction. “Securing funding to aggressively pursue the first phase of our lithium growth opportunity has been an important goal for our management team. This strategic investment will help advance our lithium project, strengthen our balance sheet and improve execution capabilities across our platform.

Approximately US$200 million of the investment proceeds are expected to be used to advance the first phase of the company’s lithium sustainability project. The remaining funds, after all transaction costs, should be used to pay down debt and help align the company’s capital structure with its growth strategy.

As part of the agreement, the companies will also explore opportunities to create value across Compass Minerals’ operating platform by leveraging the extensive capabilities of KII’s many operating subsidiaries, including in the areas of supply and supply of fuel and raw materials, freight and logistics synergies. , and assistance with engineering and project development.

Read the article online at: https://www.globalminingreview.com/mining/16092022/compass-minerals-announce-equity-investment-partnership-with-koch-minerals-and-trading/

]]>
Dong-A ST signs equity investment and license agreement with Nasdaq-listed NeuroBo https://brlspeak.net/dong-a-st-signs-equity-investment-and-license-agreement-with-nasdaq-listed-neurobo/ Fri, 16 Sep 2022 02:41:31 +0000 https://brlspeak.net/dong-a-st-signs-equity-investment-and-license-agreement-with-nasdaq-listed-neurobo/ [Source: Dong-A ST] Dong-A ST has agreed to take a stake in Nasdaq-listed NeuroBo Pharmaceuticals and transfer its treatment candidate for non-alcoholic steatohepatitis (NASH), obesity and type 2 diabetes, the Korean company announced Thursday. . The deal could make the Korean pharmaceutical company the largest shareholder in the Boston-based biotech company, a clinical-stage biotech company […]]]>

[Source: Dong-A ST]

Dong-A ST has agreed to take a stake in Nasdaq-listed NeuroBo Pharmaceuticals and transfer its treatment candidate for non-alcoholic steatohepatitis (NASH), obesity and type 2 diabetes, the Korean company announced Thursday. .

The deal could make the Korean pharmaceutical company the largest shareholder in the Boston-based biotech company, a clinical-stage biotech company historically focused on therapies for neurodegenerative, infectious and cardiometabolic diseases, which is expected to play a role in the korean society research. and drug development center targeting the global market.

Under the license agreement, NeuroBo will have exclusive worldwide rights to develop and commercialize Dong-A ST’s DA-1241 and DA-1726, which are being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). ), obesity and type 2 diabetes.

Dong-A ST will manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Korea, while NeuroBo will be responsible for global development, regulatory and commercial activities other than for certain Asia-Pacific geographies.

Dong-A ST will receive an initial payment of $22 million in Series A Convertible Preferred Shares, which will automatically convert into NeuroBo common stock, and will be eligible to receive commercial and regulatory milestone payments up to a value of $316 million, depending on the achievement of specific regulatory and commercial changes. Dong-A ST will also be entitled to single-digit royalties on net sales of the two assets.

Dong-A ST will also commit $15 million to fund the assets, subject to NeuroBo’s ability to secure additional funding worth $30 million under the license agreement. NeuroBo plans to raise funds in the capital market next month. Once the financing is finalized, Dong-A ST will invest some 50 billion won ($35.8 million) to secure a 50.8% stake in NeuroBo.

Shares of Dong-A ST edged down 0.18% to 55,800 won in early trading on Friday.

By Chung Seul-gi and Minu Kim

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]

]]>
Dong-A ST Signs Licensing and Capital Investment Agreement with U.S. Biotech Company NeuroBo https://brlspeak.net/dong-a-st-signs-licensing-and-capital-investment-agreement-with-u-s-biotech-company-neurobo/ Thu, 15 Sep 2022 02:17:57 +0000 https://brlspeak.net/dong-a-st-signs-licensing-and-capital-investment-agreement-with-u-s-biotech-company-neurobo/ [Courtesy of Dong-A ST] SEOUL – NeuroBo Pharmaceuticals, a clinical-stage biotechnology company in the United States, will become an overseas base for new drug development and sales of Dong-A ST, a pharmaceutical company in South Korea, as part of a worldwide license and participation agreement. The objective is to become NeuroBo’s largest shareholder if it […]]]>

[Courtesy of Dong-A ST]

SEOUL – NeuroBo Pharmaceuticals, a clinical-stage biotechnology company in the United States, will become an overseas base for new drug development and sales of Dong-A ST, a pharmaceutical company in South Korea, as part of a worldwide license and participation agreement. The objective is to become NeuroBo’s largest shareholder if it succeeds in raising funds.

NeuroBo will receive exclusive worldwide development rights to DA-1241, a new drug candidate for the treatment of type 2 diabetes and non-alcoholic fatty hepatitis, and DA-1726 for the treatment of obesity and non-alcoholic fatty hepatitis, as well as with exclusive sales rights worldwide, except for South Korea.

Dong-A ST said it was responsible for clinical trial samples and post-marketing production, while NeuroBo was responsible for clinical development, licensing and sales. The Boston-based biotech company develops multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases.

Dong-A ST will acquire a $22 million deposit from NeuroBo in the form of convertible preferred stock and will receive up to $316 million in milestones based on development stage performance. After commercialization, royalties may be paid depending on the size of the sales.

Dong-A ST, a unit of Dong-A Socio Group, said it would invest $15 million to control a 50.8% stake in NeuroBo. The purchase of shares is scheduled for October 31. “The signing of this contract will unite the R&D capabilities of both companies to accelerate the development of excellent treatments,” Dong-A ST CEO Kim Min-young said in a statement released on September 15.

NeuroBo would be used as the global R&D base of Dong-A Socio Holdings, which is mainly engaged in the production and sale of pharmaceuticals.

DA-1241 is a treatment for type 2 diabetes with a GPR119 (G protein-coupled receptor 119) agonist mechanism. DA-1241 improves hyperglycemia by inhibiting hepatic gluconeogenesis and improving insulin secretion, Dong-A ST said, adding that it has been confirmed that it has the possibility of developing a treatment for hepatitis. non-alcoholic greasy.

DA-1726 is a new first-in-class drug that treats obesity in the family of oxyntomodulin analogs. It acts simultaneously on GLP-1 receptors and glucagon receptors to inhibit appetite, promote insulin secretion, and increase basal metabolic rate at the peripheral stage, ultimately resulting in weight loss. Dong-A ST said that the therapeutic effect of DA-1726 on non-alcoholic fatty liver disease has also been confirmed.


© Aju Business Daily & www.ajunews.com Copyright: Nothing on this site may be reproduced, distributed, transmitted, displayed, published or broadcast without the permission of Aju News Corporation.

]]>